Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 83 figures, this 153-page report ?North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

“Third, Biogen’s been running on fumes while it works on its Alzheimer’s drug, but the fumes, basically a very good MS drug ... also develops various products for disorders like Parkinson ...

The green light from the FDA puts further pressure on Biogen, currently grappling with weaker sales of its MS products, pipeline setbacks, and misfired launches that have forced it to slash staff ...

Communications agency Pegasus was given a brief to create an engaging platform capable of improving the understanding of MS and one of Biogen’s products among MS professionals. The result was MS ...

Launched in 2018, the Morningstar Minority Empowerment Index highlights companies that demonstrate a strong commitment to ...